BG
Bellevue Group Portfolio holdings
AUM
$4.54B
This Quarter Return
-11.11%
1 Year Return
+22.5%
3 Year Return
+98.22%
5 Year Return
+159.37%
10 Year Return
–
AUM
$7.07B
AUM Growth
-$1.54B
(-18%)
Cap. Flow
-$234M
Cap. Flow
% of AUM
-3.31%
Top 10 Holdings %
Top 10 Hldgs %
34.72%
Holding
187
New
10
Increased
57
Reduced
82
Closed
15
Top Buys
| 1 |
Intuitive Surgical
ISRG
|
$58.1M |
| 2 |
Pfizer
PFE
|
$41.4M |
| 3 |
Harmony Biosciences
HRMY
|
$28.1M |
| 4 |
Jazz Pharmaceuticals
JAZZ
|
$25.4M |
| 5 |
Celldex Therapeutics
CLDX
|
$24.9M |
Top Sells
| 1 |
Elevance Health
ELV
|
$98M |
| 2 |
Vertex Pharmaceuticals
VRTX
|
$85.7M |
| 3 |
AbbVie
ABBV
|
$47.7M |
| 4 |
Bristol-Myers Squibb
BMY
|
$46.5M |
| 5 |
Regeneron Pharmaceuticals
REGN
|
$42.9M |
Sector Composition
| 1 | Healthcare | 98.26% |
| 2 | Industrials | 0.38% |
| 3 | Energy | 0.03% |
| 4 | Communication Services | 0.01% |
| 5 | Technology | 0.01% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
26
Insulet
PODD
$24.2B
| $84.2M | 1.19% |
386,335
-11,854
| -3% | -$2.58M |
|
27
Option Care Health
OPCH
$4.7B
| $80.2M | 1.13% |
2,887,259
-345,528
| -11% | -$9.6M |
|
28
Tandem Diabetes Care
TNDM
$834M
| $77.9M | 1.1% |
1,315,873
+199,365
| +18% | +$11.8M |
|
29
Inspire Medical Systems
INSP
$2.53B
| $74.4M | 1.05% |
407,057
+9,551
| +2% | +$1.74M |
|
|
MYOV
30
DELISTED
Myovant Sciences Ltd.
MYOV
| $73.6M | 1.04% |
5,919,639
+60,600
| +1% | +$753K |
|
31
Insmed
INSM
$30.3B
| $71.4M | 1.01% |
3,621,562
+69,786
| +2% | +$1.38M |
|
|
SWAV
32
DELISTED
Shockwave Medical, Inc. Common Stock
SWAV
| $70.9M | 1% |
370,699
-27,878
| -7% | -$5.33M |
|
33
Molina Healthcare
MOH
$9.6B
| $69.4M | 0.98% |
248,313
-54,484
| -18% | -$15.2M |
|
34
DexCom
DXCM
$30.9B
| $69.2M | 0.98% |
928,508
-11,092
| -1% | -$827K |
|
35
Humana
HUM
$37.5B
| $68M | 0.96% |
145,309
-2,133
| -1% | -$998K |
|
36
Relay Therapeutics
RLAY
$709M
| $67.5M | 0.95% |
4,032,262
+113,300
| +3% | +$1.9M |
|
37
Revolution Medicines
RVMD
$7.43B
| $65.9M | 0.93% |
3,383,262
+72,600
| +2% | +$1.41M |
|
38
Evolent Health
EVH
$1.11B
| $62M | 0.88% |
2,018,521
-593,742
| -23% | -$18.2M |
|
|
AMED
39
DELISTED
Amedisys
AMED
| $61.5M | 0.87% |
585,154
+9,023
| +2% | +$948K |
|
40
Medtronic
MDT
$118B
| $57.9M | 0.82% |
645,506
-10,524
| -2% | -$945K |
|
41
CRISPR Therapeutics
CRSP
$4.82B
| $56M | 0.79% |
922,005
-4,900
| -0.5% | -$298K |
|
42
Exelixis
EXEL
$9.95B
| $55.8M | 0.79% |
2,678,500
-40,500
| -1% | -$843K |
|
43
Apellis Pharmaceuticals
APLS
$3.51B
| $54.6M | 0.77% |
1,206,422
+107,710
| +10% | +$4.87M |
|
44
CareDx
CDNA
$678M
| $54.5M | 0.77% |
2,537,524
+226,348
| +10% | +$4.86M |
|
45
Cigna
CI
$80.2B
| $51M | 0.72% |
193,657
-65,489
| -25% | -$17.3M |
|
46
Charles River Laboratories
CRL
$7.99B
| $49.4M | 0.7% |
231,069
+104,663
| +83% | +$22.4M |
|
47
HCA Healthcare
HCA
$95.4B
| $49.2M | 0.7% |
292,771
-7,426
| -2% | -$1.25M |
|
48
Omnicell
OMCL
$1.51B
| $48.4M | 0.68% |
425,823
+63,491
| +18% | +$7.22M |
|
49
Centene
CNC
$14.8B
| $46.2M | 0.65% |
545,903
-114,732
| -17% | -$9.71M |
|
50
Bio-Rad Laboratories Class A
BIO
$7.8B
| $45.1M | 0.64% |
91,161
+19,152
| +27% | +$9.48M |
|